Advertisement

Related Videos

Amit Sanyal, MD: A Clinician’s Perspective

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Advertisement

Advertisement




Nov
09
Today In Oncology
HERON-Lung01 HER3-Directed ADC Prolongs PFS in EGFR-Mutated Advanced NSCLC
Two Forever Chemicals Associated Higher Risk of ER-Negative Breast Cancer
Methylphenidate May Reduce Cancer-Related Fatigue in Patients With Hematologic Malignancies
Extended Follow-up of Nivolumab Ipilimumab for Localized dMMR MSI-H Gastric GEJ Cancer
Claudia Henschke, PhD, MD Finding Lung Cancer in Time
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo